Patents by Inventor Zenichi Ikeda
Zenichi Ikeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11459325Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: January 30, 2019Date of Patent: October 4, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
-
Publication number: 20220289679Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 15, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Publication number: 20220274982Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 1, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
-
Publication number: 20210115048Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.Type: ApplicationFiled: April 26, 2018Publication date: April 22, 2021Inventors: Shuji KITAMURA, Zenichi IKEDA, Minoru IKOMA, Koji WATANABE, Hideki HIROSE, Takafumi YUKAWA, Sachie MORIMOTO, Naoki NISHIZAWA, Taiji ASAMI
-
Publication number: 20210087186Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: January 30, 2019Publication date: March 25, 2021Applicant: Takeda Pharmaceutical Company LimitedInventors: Yuta TANAKA, Tomohiro OHASHI, Zenichi IKEDA, Yuta TANAKA, Florian PÜNNER, Takeshi YAMAMOTO, Keiko KAKEGAWA, Fumiaki KIKUCHI, Nao MORISHITA, Takahito KASAHARA, Masaki SETO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Satoshi MIKAMI, Minoru SASAKI
-
Patent number: 10919891Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.Type: GrantFiled: April 26, 2018Date of Patent: February 16, 2021Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shuji Kitamura, Zenichi Ikeda, Sachie Morimoto, Minoru Ikoma, Koji Watanabe, Hideki Hirose, Takafumi Yukawa, Kenjiro Sato
-
Patent number: 10875862Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.Type: GrantFiled: April 26, 2018Date of Patent: December 29, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shuji Kitamura, Zenichi Ikeda, Sachie Morimoto, Minoru Ikoma, Koji Watanabe, Hideki Hirose, Takafumi Yukawa, Kenjiro Sato
-
Publication number: 20200131174Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.Type: ApplicationFiled: April 26, 2018Publication date: April 30, 2020Inventors: Shuji KITAMURA, Zenichi IKEDA, Sachie MORIMOTO, Minoru IKOMA, Koji WATANABE, Hideki HIROSE, Takafumi YUKAWA, Kenjiro SATO
-
Patent number: 10435399Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 30, 2018Date of Patent: October 8, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Masahiro Ito, Hideyuki Sugiyama, Osamu Kubo, Fumiaki Kikuchi, Takeshi Yasui, Keiko Kakegawa, Zenichi Ikeda, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Akinori Toita, Takuto Kojima, Yasutomi Asano, Ayumu Sato, Hironobu Maezaki, Shinobu Sasaki, Hironori Kokubo, Misaki Homma, Minoru Sasaki, Yasuhiro Imaeda
-
Publication number: 20190135799Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 30, 2018Publication date: May 9, 2019Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Osamu KUBO, Fumiaki KIKUCHI, Takeshi YASUI, Keiko KAKEGAWA, Zenichi IKEDA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Akinori TOITA, Takuto KOJIMA, Yasutomi ASANO, Ayumu SATO, Hironobu MAEZAKI, Shinobu SASAKI, Hironori KOKUBO, Misaki HOMMA, Minoru SASAKI, Yasuhiro IMAEDA
-
Patent number: 10023544Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: GrantFiled: February 12, 2015Date of Patent: July 17, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
-
Patent number: 10017487Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].Type: GrantFiled: March 25, 2016Date of Patent: July 10, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Keiko Kakegawa, Zenichi Ikeda, Minoru Sasaki, Fumiaki Kikuchi, Yoichi Nishikawa
-
Patent number: 9975903Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: GrantFiled: December 24, 2015Date of Patent: May 22, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
-
Patent number: 9969705Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: GrantFiled: February 12, 2015Date of Patent: May 15, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Zenichi Ikeda, Yoichi Nishikawa
-
Publication number: 20180072694Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: March 25, 2016Publication date: March 15, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Keiko Kakegawa, Zenichi IKEDA, Minoru SASAKI, Fumiaki KIKUCHI, Yoichi NISHIKAWA
-
Publication number: 20170349605Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].Type: ApplicationFiled: December 24, 2015Publication date: December 7, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Minoru SASAKI, Fumiaki KIKUCHI, Zenichi IKEDA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Shigekazu SASAKI, Koichiro FUKUDA, Kazuaki TAKAMI, Yoshihiro BANNO, Masahiro KAMAURA
-
Publication number: 20160355494Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: ApplicationFiled: February 12, 2015Publication date: December 8, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Minoru SASAKI, Keiko KAKEGAWA, Fumiaki KIKUCHI, Zenichi IKEDA, Yoichi NISHIKAWA
-
Publication number: 20160347724Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: ApplicationFiled: February 12, 2015Publication date: December 1, 2016Applicant: Takeda Pharmaceutical Company LimitedInventors: Zenichi IKEDA, Minoru SASAKI, Keiko KAKEGAWA, Fumiaki KIKUCHI, Yoichi NISHIKAWA
-
Patent number: 9428470Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: GrantFiled: February 11, 2015Date of Patent: August 30, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
-
Patent number: 9346776Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.Type: GrantFiled: February 11, 2015Date of Patent: May 24, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa